MX352844B - Compuestos de quinolina sustituidos y metodos de uso. - Google Patents

Compuestos de quinolina sustituidos y metodos de uso.

Info

Publication number
MX352844B
MX352844B MX2013007278A MX2013007278A MX352844B MX 352844 B MX352844 B MX 352844B MX 2013007278 A MX2013007278 A MX 2013007278A MX 2013007278 A MX2013007278 A MX 2013007278A MX 352844 B MX352844 B MX 352844B
Authority
MX
Mexico
Prior art keywords
methods
substituted quinoline
quinoline compounds
compounds
compositions
Prior art date
Application number
MX2013007278A
Other languages
English (en)
Other versions
MX2013007278A (es
Inventor
Xi Ning
Original Assignee
Calitor Sciences Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Calitor Sciences Llc filed Critical Calitor Sciences Llc
Publication of MX2013007278A publication Critical patent/MX2013007278A/es
Publication of MX352844B publication Critical patent/MX352844B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a compuestos de quinolina sustituidos novedosos, sales farmacéuticamente aceptables y formulaciones de las mismas útiles en modular la actividad de proteína tirosina quinasa, y en modular actividades celulares tales como proliferación, diferenciación, apóptosis, migración e invasión. La invención también proporciona composiciones farmacéuticamente aceptables que comprenden tales compuestos y métodos de usar las composiciones en el tratamiento de trastornos hiperproliferativos en mamíferos, especialmente humanos.
MX2013007278A 2011-02-28 2012-02-21 Compuestos de quinolina sustituidos y metodos de uso. MX352844B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161447104P 2011-02-28 2011-02-28
PCT/US2012/025834 WO2012118632A1 (en) 2011-02-28 2012-02-21 Substituted quinoline compounds and methods of use

Publications (2)

Publication Number Publication Date
MX2013007278A MX2013007278A (es) 2013-09-13
MX352844B true MX352844B (es) 2017-12-11

Family

ID=46719110

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013007278A MX352844B (es) 2011-02-28 2012-02-21 Compuestos de quinolina sustituidos y metodos de uso.

Country Status (14)

Country Link
US (2) US9133162B2 (es)
EP (1) EP2680886B1 (es)
JP (1) JP5707518B2 (es)
KR (1) KR101546693B1 (es)
AU (1) AU2012223639B2 (es)
BR (1) BR112013014708B1 (es)
CA (1) CA2820709C (es)
ES (1) ES2590778T3 (es)
MX (1) MX352844B (es)
MY (1) MY181439A (es)
RU (1) RU2568258C2 (es)
SG (1) SG190735A1 (es)
WO (1) WO2012118632A1 (es)
ZA (1) ZA201303793B (es)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4834553B2 (ja) * 2004-09-17 2011-12-14 エーザイ・アール・アンド・ディー・マネジメント株式会社 医薬組成物
EP1925676A4 (en) 2005-08-02 2010-11-10 Eisai R&D Man Co Ltd TEST METHOD FOR THE EFFECT OF A VASCULARIZATION INHIBITOR
JPWO2007052849A1 (ja) 2005-11-07 2009-04-30 エーザイ・アール・アンド・ディー・マネジメント株式会社 血管新生阻害物質とｃ−ｋｉｔキナーゼ阻害物質との併用
RU2448708C3 (ru) * 2006-05-18 2017-09-28 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Противоопухолевое средство против рака щитовидной железы
WO2008093855A1 (ja) * 2007-01-29 2008-08-07 Eisai R & D Management Co., Ltd. 未分化型胃癌治療用組成物
KR101513326B1 (ko) * 2007-11-09 2015-04-17 에자이 알앤드디 매니지먼트 가부시키가이샤 혈관 신생 저해 물질과 항종양성 백금 착물의 병용
CN105362277A (zh) 2008-07-16 2016-03-02 药品循环有限公司 用于实体肿瘤的治疗的布鲁顿酪氨酸激酶的抑制剂
TH121482A (th) 2009-08-19 2013-02-28 นางสาวปัณณพัฒน์ เหลืองธาตุทอง องค์ประกอบทางเภสัชกรรมที่ประกอบด้วยอนุพันธ์ของควิโนลีน
CA3007787C (en) 2010-06-03 2020-03-10 Pharmacyclics Llc The use of inhibitors of bruton's tyrosine kinase (btk)
AU2011270165B2 (en) 2010-06-25 2015-12-24 Eisai R&D Management Co., Ltd. Antitumor agent using compounds having kinase inhibitory effect in combination
KR101940340B1 (ko) 2011-03-04 2019-01-18 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 키나제 억제제로서의 아미노-퀴놀린
WO2012144463A1 (ja) * 2011-04-18 2012-10-26 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍治療剤
EP3444363B1 (en) 2011-06-03 2020-11-25 Eisai R&D Management Co., Ltd. Biomarkers for prediciting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
BR112014000653A2 (pt) 2011-07-13 2017-02-14 Pharmacyclics Inc inibidores de tirosina quinase de bruton
TWI547494B (zh) 2011-08-18 2016-09-01 葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之胺基喹唑啉類
WO2013067165A1 (en) 2011-11-02 2013-05-10 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitors with platinum-containing agents
WO2013074594A1 (en) * 2011-11-14 2013-05-23 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitors with braf inhibitors
CN102643268B (zh) * 2011-12-30 2014-05-21 沈阳药科大学 喹啉类及噌啉类化合物及其应用
WO2013180949A1 (en) * 2012-05-27 2013-12-05 Ning Xi Substituted quinoline compounds and methods of use
CA2879570A1 (en) 2012-07-24 2014-01-30 Pharmacyclics, Inc. Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk)
US8975282B2 (en) 2012-07-28 2015-03-10 Sunshine Lake Pharma Co., Ltd. Substituted pyrazolone compounds and methods of use
MX2015001424A (es) 2012-07-28 2016-03-09 Calitor Sciences Llc Compuestos pirazolona sustituidos y metodos de uso.
AR092529A1 (es) 2012-09-13 2015-04-22 Glaxosmithkline Llc Compuesto de aminoquinazolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento
AR092530A1 (es) * 2012-09-13 2015-04-22 Glaxosmithkline Llc Compuesto de amino-quinolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento
KR101738063B1 (ko) 2012-09-21 2017-05-19 아로그 파마슈티칼스, 인코퍼레이티드 구조적으로 활성인 인산화된 ｆｌｔ３ 키나제의 억제 방법
CN103724349A (zh) * 2012-10-11 2014-04-16 韩冰 一类治疗脑性瘫痪的化合物及其用途
EP2911673A4 (en) * 2012-10-25 2016-05-18 Novartis Ag COMBINATION
US20150328320A1 (en) * 2012-11-30 2015-11-19 Glaxosmithkline Llc Novel Pharmaceutical Composition
RU2015115397A (ru) 2012-12-21 2017-01-25 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Аморфная форма производного хинолина и способ его получения
BR112015019624A2 (pt) 2013-02-21 2017-07-18 Glaxosmithkline Ip Dev Ltd quinazolinas como inibidores de quinase
EA031493B9 (ru) * 2013-04-08 2019-12-18 Байер Фарма Акциенгезельшафт Комбинация и фармацевтическая композиция для лечения или профилактики неходжкинской лимфомы (нхл)
ES2687968T3 (es) 2013-05-14 2018-10-30 Eisai R&D Management Co., Ltd. Biomarcadores para pronosticar y evaluar la reactividad de sujetos con cáncer de endometrio a compuestos con lenvatinib
ES2709509T3 (es) * 2013-08-12 2019-04-16 Pharmacyclics Llc Procedimientos para el tratamiento de cáncer amplificado por HER2
CN103788067A (zh) * 2014-01-14 2014-05-14 北京万全德众医药生物技术有限公司 一种3-[3-乙氧基-4-(n-邻苯二甲先亚胺基)]苯氨基-n-[3-氯-4-(2-吡啶基甲氧基)]苯基-2-氰基-2-丙烯酰胺的制备方法
WO2015142867A1 (en) * 2014-03-18 2015-09-24 Stc.Unm Synergistic enhancement of 5-fluorouracil cytotoxicity by deoxyuridine analogs in cancer cells
EP3119910A4 (en) 2014-03-20 2018-02-21 Pharmacyclics LLC Phospholipase c gamma 2 and resistance associated mutations
JP6500037B2 (ja) 2014-04-22 2019-04-10 キャリター・サイエンシーズ・リミテッド・ライアビリティ・カンパニーＣａｌｉｔｏｒ Ｓｃｉｅｎｃｅｓ， Ｌｌｃ 二環式ピラゾロン化合物および使用方法
CN104119317B (zh) * 2014-07-25 2016-08-17 沈阳药科大学 含1,2,3-三氮唑的喹啉类化合物及其制备方法和应用
KR20230043234A (ko) 2014-08-28 2023-03-30 에자이 알앤드디 매니지먼트 가부시키가이샤 고순도의 퀴놀린 유도체 및 이를 제조하는 방법
US9867831B2 (en) * 2014-10-01 2018-01-16 Boehringer Ingelheim International Gmbh Combination treatment of acute myeloid leukemia and myelodysplastic syndrome
LT3263106T (lt) 2015-02-25 2024-01-10 Eisai R&D Management Co., Ltd. Chinolino darinių kartumo sumažinimo būdas
KR102662228B1 (ko) 2015-03-04 2024-05-02 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
CN112028825B (zh) * 2015-04-07 2025-03-14 广东众生睿创生物科技有限公司 酪氨酸激酶抑制剂及包含该酪氨酸激酶抑制剂的药物组合物
MX385083B (es) * 2015-04-14 2025-03-14 Qurient Co Ltd Derivados de quinolina como inhibidores de tirosinas-cinasas de receptor de met de axl, mer y tyro 3 (tam rtk).
WO2016183071A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Hetero-tricyclic compounds and their use for the treatment of cancer
MX373231B (es) 2015-06-16 2020-05-08 Eisai R&D Man Co Ltd Agente anticancerigeno.
WO2017027717A1 (en) 2015-08-12 2017-02-16 Incyte Corporation Bicyclic fused pyrimidine compounds as tam inhibitors
CA2994925C (en) 2015-08-20 2023-08-29 Eisai R&D Management Co., Ltd. Tumor therapeutic agent
WO2017035366A1 (en) 2015-08-26 2017-03-02 Incyte Corporation Pyrrolopyrimidine derivatives as tam inhibitors
CN106632253B (zh) * 2015-11-02 2019-03-22 广东东阳光药业有限公司 一种取代的喹啉化合物的晶型及其药物组合物和用途
CN106632254B (zh) * 2015-11-02 2019-03-01 广东东阳光药业有限公司 一种取代的喹啉化合物的晶型及其药物组合物和用途
EP3373934B1 (en) * 2015-11-14 2020-05-20 Sunshine Lake Pharma Co., Ltd. Crystalline form of a substituted quinoline compound and pharmaceutical compositions thereof
WO2017083788A1 (en) * 2015-11-14 2017-05-18 Sunshine Lake Pharma Co., Ltd. Crystalline form of a substituted quinoline compound and pharmaceutical compositions thereof
CN105330646B (zh) * 2015-12-04 2019-05-24 上海勋和医药科技有限公司 一种抗肿瘤药马来酸来那替尼的制备方法
AU2017241524B2 (en) 2016-03-28 2021-07-08 Incyte Corporation Pyrrolotriazine compounds as TAM inhibitors
KR101796684B1 (ko) 2016-05-19 2017-11-10 건국대학교 산학협력단 케라틴 8 인산화 억제제를 포함하는 황반변성 예방 또는 치료용 약학 조성물 및 황반변성 치료제의 스크리닝 방법
WO2017218365A1 (en) * 2016-06-16 2017-12-21 Sunshine Lake Pharma Co., Ltd. Crystalline form of a substituted quinoline compound and pharmaceutical compositions thereof
CN107641099A (zh) * 2016-07-20 2018-01-30 广东东阳光药业有限公司 取代的4‑羟基喹啉类化合物的制备方法
WO2018026877A1 (en) * 2016-08-05 2018-02-08 Calitor Sciences, Llc Process for preparing substituted quinolin-4-ol compounds
US10980792B2 (en) 2016-09-12 2021-04-20 Zhuhai Beihai Biotech Co., Ltd. Formulations of Cabozantinib
CN106749231B (zh) * 2016-10-09 2019-03-01 南京纳丁菲医药科技有限公司 萘啶化合物和药物组合物及它们的应用
RU2644155C1 (ru) * 2016-12-12 2018-02-08 Закрытое акционерное общество "Р-Фарм" (ЗАО "Р-Фарм") 2-(3-(4-(7H-пирроло[2,3-d]пиримидин-4-ил)-1H-пиразол-1-ил)-1-(этилсульфонил)азетидин-3-ил)ацетонитрила геминафтилдисульфонат в качестве ингибитора Янус киназ
MX393780B (es) 2017-01-17 2025-03-24 Heparegenix Gmbh Inhibidores de proteina cinasa para promover la regeneracion hepatica o reducir o prevenir la muerte de hepatocitos
US12303505B2 (en) 2017-02-08 2025-05-20 Eisai R&D Management Co., Ltd. Tumor-treating pharmaceutical composition
US11166953B2 (en) 2017-04-17 2021-11-09 Yale University Compounds, compositions and methods of treating or preventing acute lung injury
BR112019023064A2 (pt) 2017-05-16 2020-06-09 Eisai R&D Man Co Ltd tratamento de carcinoma hepatocelular
TWI821200B (zh) 2017-09-27 2023-11-11 美商英塞特公司 Tam抑制劑之鹽
CN111372925B (zh) * 2017-11-24 2022-09-02 南京明德新药研发有限公司 作为c-MET/AXL抑制剂的尿嘧啶类化合物
BR112020021370A2 (pt) * 2018-05-30 2021-01-19 Qurient Co., Ltd. Derivados de quinolina como inibidores de rtk e csf1r axl/mer
EP3810596B1 (en) * 2018-06-01 2022-11-30 Rigel Pharmaceuticals, Inc. Quinoline derivatives useful as tyrosine kinase inhibitors
US11241438B2 (en) 2018-06-29 2022-02-08 Incyte Corporation Formulations of an AXL/MER inhibitor
CN110845406B (zh) * 2019-12-04 2021-07-20 广州安岩仁医药科技有限公司 喹啉类化合物的制备方法
EP4114401A1 (en) 2020-03-06 2023-01-11 Incyte Corporation Combination therapy comprising axl/mer and pd-1/pd-l1 inhibitors
CN111440177B (zh) * 2020-05-25 2022-06-14 辽宁大学 一种取代吡唑并[1,5-a]嘧啶类化合物及其制备方法和应用
CN113912628B (zh) * 2020-07-10 2023-05-02 北京范恩柯尔生物科技有限公司 三嗪类化合物及其组合物和用途

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
US5886026A (en) 1993-07-19 1999-03-23 Angiotech Pharmaceuticals Inc. Anti-angiogenic compositions and methods of use
KR100392057B1 (ko) 1993-11-30 2003-10-30 맥길 유니버시티 세포의 CpG 디뉴클레오티드 내의 시토신의 메틸화를 감소하는 방법
US5578716A (en) 1993-12-01 1996-11-26 Mcgill University DNA methyltransferase antisense oligonucleotides
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
US6268137B1 (en) 1996-05-22 2001-07-31 Methylgene, Inc. Specific inhibitors of DNA methyl transferase
AU8125098A (en) 1997-05-30 1998-12-30 Mcgill University Dna methyltransferase genomic sequences and antisense oligonucleotides
US6020318A (en) 1997-05-30 2000-02-01 Methylgene, Inc. DNA methyltransferase genomic sequences and antisense oligonucleotides
US6066625A (en) 1998-02-03 2000-05-23 Methylgene, Inc. Optimized antisense oligonucleotides complementary to DNA methyltransferase sequences
US6953783B1 (en) 1998-10-19 2005-10-11 Methylgene, Inc. Modulation of gene expression by combination therapy
JP2003500052A (ja) 1999-05-03 2003-01-07 メチルジーン インコーポレイテッド ヒストン脱アセチル酵素の抑制
EP1233958B1 (en) 1999-11-23 2011-06-29 MethylGene Inc. Inhibitors of histone deacetylase
CA2408385A1 (en) 2000-03-24 2001-09-24 Methylgene, Inc. Inhibition of specific histone deacetylase isoforms
EP1280764B1 (en) 2000-03-24 2010-11-24 Methylgene, Inc. Inhibitors of histone deacetylase
JP3795044B2 (ja) 2001-09-14 2006-07-12 メシルジーン、インコーポレイテッド ヒストンデアセチラーゼの阻害剤
US7868204B2 (en) 2001-09-14 2011-01-11 Methylgene Inc. Inhibitors of histone deacetylase
US6897220B2 (en) 2001-09-14 2005-05-24 Methylgene, Inc. Inhibitors of histone deacetylase
KR20050074487A (ko) 2002-10-17 2005-07-18 메틸진, 인크. 히스톤 데아세틸라아제의 억제제
WO2005030704A1 (en) 2003-09-24 2005-04-07 Methylgene, Inc. Inhibitors of histone deacetylase
WO2005092899A1 (en) 2004-03-26 2005-10-06 Methylgene Inc. Inhibitors of histone deacetylase
ES2438017T3 (es) 2004-07-30 2014-01-15 Methylgene Inc. Inhibidores de la señalización del receptor del VEGF y del receptor del HGF
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
NZ564283A (en) 2005-05-20 2011-07-29 Methylgene Inc Inhibitors of VEGF receptor and HGF receptor signaling
US7732613B2 (en) 2005-09-14 2010-06-08 Bristol-Myers Squibb Company Met kinase inhibitors
US7880004B2 (en) 2005-09-15 2011-02-01 Bristol-Myers Squibb Company Met kinase inhibitors
CA2645137A1 (en) 2006-03-07 2007-09-13 James F. Blake Heterobicyclic pyrazole compounds and methods of use
CA2652417A1 (en) 2006-05-19 2008-04-24 Bayer Healthcare Ag Pyridonecarboxamide derivatives useful in treating hyper-proliferative and angiogenesis disorders
WO2008035209A2 (en) 2006-05-30 2008-03-27 Methylgene Inc. Inhibitors of protein tyrosine kinase activity
CA2655128A1 (en) 2006-06-08 2007-12-21 Array Biopharma Inc. Quinoline compounds and methods of use
ES2449482T3 (es) 2007-01-09 2014-03-19 Amgen Inc. Derivados de bis-aril-amida útiles para el tratamiento de cáncer
WO2009005813A1 (en) 2007-07-02 2009-01-08 Wyeth Modulators of axl for use in treating bone disorders
WO2009096435A1 (ja) 2008-01-29 2009-08-06 Takeda Pharmaceutical Company Limited 縮合複素環誘導体およびその用途
CN101952287B (zh) 2008-02-28 2013-11-27 默克专利有限公司 蛋白激酶抑制剂及其应用
US8445509B2 (en) 2008-05-08 2013-05-21 Takeda Pharmaceutical Company Limited Fused heterocyclic derivatives and use thereof
MX2010012290A (es) * 2008-05-14 2011-02-21 Amgen Inc Combinaciones de inhibidores del receptor del factor de crecimiento endotelial vascular e inhibidores del factor de crecimiento de hepatocito para el tratamiento de cancer.
TWI365185B (en) 2008-07-24 2012-06-01 Lilly Co Eli Amidophenoxyindazoles useful as inhibitors of c-met
AU2009300328A1 (en) * 2008-10-01 2010-04-08 Ludwig Institute For Cancer Research Methods for the treatment of cancer
AU2009303602B2 (en) * 2008-10-14 2012-06-14 Sunshine Lake Pharma Co., Ltd. Compounds and methods of use
KR100961410B1 (ko) 2008-10-14 2010-06-09 (주)네오팜 단백질 키나제 억제제로서 헤테로사이클릭 화합물
KR20110133048A (ko) 2009-03-21 2011-12-09 닝 시 아미노 에스테르 유도체, 그의 염 및 이용 방법
SG178271A1 (en) 2009-08-06 2012-03-29 Merck Patent Gmbh Novel bicyclic urea compounds
CN102086211B (zh) 2009-12-08 2013-09-11 广东东阳光药业有限公司 作为蛋白激酶抑制剂的芳杂环化合物
CN102212062B (zh) 2010-04-02 2015-04-29 广东东阳光药业有限公司 氨基酯类衍生物及其盐和使用方法
CA2805148C (en) 2010-07-14 2016-01-19 Zhejiang Beta Pharma Inc. Novel fused heterocyclic derivatives useful as c-met tyrosine kinase inhibitors
WO2012008564A1 (ja) 2010-07-16 2012-01-19 協和発酵キリン株式会社 含窒素芳香族複素環誘導体
KR20130108318A (ko) 2010-08-27 2013-10-02 메르크 파텐트 게엠베하 푸로피리딘 유도체들
EP2423208A1 (en) 2010-08-28 2012-02-29 Lead Discovery Center GmbH Pharmaceutically active compounds as Axl inhibitors
JP2013537918A (ja) 2010-09-27 2013-10-07 エクセリクシス， インク． 去勢抵抗性前立腺癌および骨芽細胞骨転移の治療のためのｍｅｔおよびｖｅｇｆの二元阻害薬
CN103420986A (zh) 2012-05-18 2013-12-04 广东东阳光药业有限公司 取代的喹啉化合物及其使用方法和用途
WO2013180949A1 (en) 2012-05-27 2013-12-05 Ning Xi Substituted quinoline compounds and methods of use

Also Published As

Publication number Publication date
ZA201303793B (en) 2014-07-30
US20120219522A1 (en) 2012-08-30
SG190735A1 (en) 2013-07-31
BR112013014708B1 (pt) 2021-10-19
BR112013014708A2 (pt) 2016-10-04
EP2680886A4 (en) 2014-08-27
RU2568258C2 (ru) 2015-11-20
HK1187259A1 (zh) 2014-04-04
CA2820709C (en) 2016-02-16
US20150342945A1 (en) 2015-12-03
MX2013007278A (es) 2013-09-13
JP5707518B2 (ja) 2015-04-30
AU2012223639B2 (en) 2015-03-19
WO2012118632A1 (en) 2012-09-07
CA2820709A1 (en) 2012-09-07
US9598400B2 (en) 2017-03-21
ES2590778T3 (es) 2016-11-23
EP2680886A1 (en) 2014-01-08
JP2014506925A (ja) 2014-03-20
KR101546693B1 (ko) 2015-08-24
RU2013135662A (ru) 2015-04-10
KR20130095806A (ko) 2013-08-28
EP2680886B1 (en) 2016-08-10
MY181439A (en) 2020-12-22
US9133162B2 (en) 2015-09-15

Similar Documents

Publication Publication Date Title
MX352844B (es) Compuestos de quinolina sustituidos y metodos de uso.
MX2015001424A (es) Compuestos pirazolona sustituidos y metodos de uso.
WO2014193647A3 (en) Alkenyl compounds and methods of use
MY180641A (en) Heteroaromatic compounds as pi3 kinase modulators and methods of use
PH12013501758A1 (en) Pyrazolo [1,5-a] pyridines as trk inhibitors
EA201391682A1 (ru) Замещенные производные индазола, активные в качестве ингибиторов киназы
EA024842B9 (ru) Соединения в качестве модуляторов протеинкиназы pi3k
HK1207069A1 (en) Heterocyclic compounds and uses thereof
EA201400772A1 (ru) Варианты полипептидов ph20, композиции на их основе и их применение
MY182036A (en) Heteroaromatic compounds as pi3 kinase modulators
EA201291098A1 (ru) Новые соединения 3,5-дизамещенного-3h-имидазо[4,5-b]пиридина и 3,5-дизамещенного -3h-[1,2,3]триазоло[4,5-b]пиридина как модуляторы протеинкиназ
WO2014019908A3 (en) Substituted pyrroles active as kinases inhibitors
AU2012284088A8 (en) Heterocyclic compounds and uses thereof
MY174196A (en) Novel fused pyrimidine derivatives for inhibition of tyrosine kinase activity
HK1199725A1 (en) Heterocyclic compounds and uses thereof
EA201070667A1 (ru) 8-замещенные пиридо[2,3-в]пиразины и их применение
MX2015014234A (es) Derivados 2-aminopirido-[4,3-d]pirimidin-5-ona y su uso como inhibidores de wee-1.
EA201491520A1 (ru) НОВЫЕ СОЕДИНЕНИЯ 3,5-ДИЗАМЕЩЕННОГО-3H-ИМИДАЗО[4,5-b]ПИРИДИНА И 3,5-ДИЗАМЕЩЕННОГО-3H-[1,2,3]ТРИАЗОЛО[4,5-b]ПИРИДИНА КАК МОДУЛЯТОРЫ C-met ПРОТЕИНКИНАЗ
MY167575A (en) Heterocyclic compounds and use thereof as modulators of type iii receptor tyrosine kinases
EA201390519A1 (ru) Замещенные соединения пиридазинкарбоксамида в качестве киназных ингибиторов
EA201401142A1 (ru) Замещенные 6-аминоникотинамиды, несущие он-содержащую группу, в качестве модуляторов kcnq2/3
HK1196609A1 (zh) 氨基喹唑啉类衍生物及其盐和使用方法
EA201690655A1 (ru) Новые соединения в качестве модуляторов протеинкиназ
EA202092370A1 (ru) Новые модуляторы киназ
HK1163450A1 (zh) 氨基酯類衍生物及其鹽和使用方法

Legal Events

Date Code Title Description
FG Grant or registration